Onconetix, Inc. Common Stock
Follow $ONCO
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $ONCO by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is ONCO moving today?
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
ONCO overview
Related filings and maps
Congress activity in ONCO
No receipt-qualified Congressional disclosure is present for ONCO in the cached public ledger.
ONCO contract awards, year to date.
Public federal awards linked to this ticker.
ONCO lobbying filings, year to date.
Registered lobbying filings matched to Onconetix, Inc. Common Stock.